Molecular You provides preventive health assessments and lifestyle coaching within the health sector. The company offers a health report based on blood profile analysis, detailing an individual's current health status and future disease risks. It serves individuals seeking personalized health care and organizations interested in population health management. It was founded in 2014 and is based in Vancouver, Canada.

Strata Oncology provides precision oncology solutions that integrate molecular profiling and decision support into cancer care. The company offers genomic sequencing services to identify tumor profiles and match patients with therapies and clinical trials. It was founded in 2015 and is based in Ann Arbor, Michigan.

BostonGene operates as a biotechnology company providing services including molecular and immune profiling, tumor microenvironment analysis, and next-generation sequencing to assist in treatment options for cancer patients. The company serves the healthcare sector, including patients, providers, and biopharma companies. It was founded in 2015 and is based in Waltham, Massachusetts.

Diagnoplex is leveraging its molecular platform capabilities to develop a colorectal cancer (CRC) screening test. Diagnoplex's lead product, Colox, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox leverages the information from nucleic acids carried by peripheral blood mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the so-called "host response", and are involved at the earliest stages of tumor formation.

First Ascent Biomedical operates within the healthcare sector, providing a drug prediction platform that includes functional drug testing, genomic sequencing, and artificial intelligence to assist in developing treatment plans for cancer patients. Their services are aimed at advanced cancer patients, oncologists, and pharmaceutical industry partners. It was founded in 2018 and is based in Miami, Florida.

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.